References
- Insights B. The cancer market outlook to 2016, 2011; 1-55. www.business-insights.com.
- Dendreon Corporation PharmaVitae Emerging Biopharma Company Analysis. Datamonitor 2012; 1-86. www.datamonitor.com.
- Market and Product Forecasts. Targeted. Cancer Ther. Datamonitor. 2011; 5-76; www.datamonitor.com.
- Datamonitor. Pipeline Insight: Thereputic Cancer Vaccines, 2009; 1-12. www.datamonitor.com.
- Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010; 12:17 - 23; PMID: 20387330
- Cancer therapy China. Gene Therapy (Gendicine). 2009; Available from: http://www.cancertherapychina.com/index.php?option=com_content&view=article&id=84&Itemid=23 Accessed on April 10, 2012.
- Datamonitor. Stakeholder opinions: Bladder cancer. New drugs needed to replace ineffective 20-year old drugs. 2008; 5-76. www.datamonitor.com.
- Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol 2009; 27:295 - 300; http://dx.doi.org/10.1007/s00345-009-0395-z; PMID: 19271220
- Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. Int J Oncol 2010; 36:1341 - 53; http://dx.doi.org/10.3892/ijo_00000619; PMID: 20428757
- Epeius Biotechnologies. Rexin-G Epeius Biotechnologies. 2009; Available from: http://www.epeiusbiotech.com/oncology-RexinG.asp Accessed on April 6, 2012.
- Shirvill J. Innovations and Opportunities in Therapeutic Vaccines. Business Insights. 2010; 5-68.
- Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011; 10:428 - 38; http://dx.doi.org/10.1038/nrd3405; PMID: 21629293
- Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars?. Health Aff (Millwood) 2006; 25:420 - 8; http://dx.doi.org/10.1377/hlthaff.25.2.420; PMID: 16522582
- Adams CP, Brantner VV. Spending on new drug development1. Health Econ 2010; 19:130 - 41; http://dx.doi.org/10.1002/hec.1454; PMID: 19247981
- DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272 - 7; http://dx.doi.org/10.1038/clpt.2009.295; PMID: 20130567
- PricewaterhouseCoopers Health Research Institute. Pharma 2020: Virtual R&D. Available from: www.pwc.com/pharma2020. 2008; Accessed on April 11, 2012.
- Schmid EF, Smith DA. Is pharmaceutical R&D just a game of chance or can strategy make a difference?. Drug Discov Today 2004; 9:18 - 26; http://dx.doi.org/10.1016/S1359-6446(04)02951-4; PMID: 14761802
- McKinsey & Company. Invention reinvented. McKinsey perspective on pharmaceutical R&D. 2010; Available from www.mckinsey.com Accessed on April 13, 2012.
- PricewaterhouseCoopers Health Research Institute. Pharma 2020: Challenging business models. 2009; Available from: www.pwc.com/pharma2020. Accessed on April 11, 2012.
- Datamonitor. Stakeholder Opinions: Gene Therapy. Gene therapy to deliver after 20 years of clinical development. 2009; 10-68. www.datamonitor.com
- Müller S, Weigelt J. Open-access public-private partnerships to enable drug discovery--new approaches. IDrugs 2010; 13:175 - 80; PMID: 20191434
- Faigen N. Pervasis acquisition puts Shire in regenerative medicine sweet spot. 2012; Available from: http://www.scripintelligence.com/home/Pervasis-acquisition-puts-Shire-in-regenerative-medicine-sweet-spot-329259 Accessed on April 13, 2012.
- Ernst & Young. Beyond borders: Global biotechnology report. 2011; 4-74. www.ey.com/Publication/vwLUAssets/Global_Biotechnology_Report_2011/$FILE/Biotech_BeyondBorders_2011.pdf
- Datamonitor. Oncology Market Access in China Market bolstered by rising incidence and improved regulatory environment. 2011; 2-61. www.datamonitor.com
- PharmaLive. Oncology Market Soars in China. 2011; Available from: http://pharmalive.com/magazines/medad/view. cfm?articleID=9544 Accessed April 13, 2012.
- Landsdell M. Innovative drug discovery in emerging markets. Business Insights. 2010; 4-51.
- Chung S. Technology Innovation and Economic Growth Korean Experiences. World Bank Workshop, 2005; 3-22.
- World Bank. Korea as a Knowledge Economy: Evolutionary Process and Lessons Learned. The World Bank, Washington D.C. 2006; 2-15.
- KFDA. Recent trends and Korea's cases in the development of gene therapy products KFDA. 2008; Available from: http://www.bioin.or.kr/upload.do?cmd=download&seq=7676&bid=industry. Accessed on April 5, 2012.